LightDark Log in Sign up

‹ Back to screener

POLYMED.NS Poly Medicure Ltd.

Healthcare

Price history

1M 6M 1Y 3Y Max
2025-08-21 ₹1964.70
2026-08-21 ₹1727.50
Change over window -12.07%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 51.5%
Trailing 20-day average 47.7%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 197416 101715 51.52%
2026-08-27 109590 45519 41.54%
2026-08-26 91740 51329 55.95%
2026-08-25 78354 36196 46.20%
2026-08-24 95827 37694 39.34%
2026-08-21 96900 54537 56.28%
2026-08-20 93919 61459 65.44%
2026-08-19 100462 44863 44.66%
2026-08-18 224876 123485 54.91%
2026-08-17 157632 74777 47.44%
2026-08-14 139114 75056 53.95%
2026-08-13 122895 63612 51.76%
2026-08-12 219951 93259 42.40%
2026-08-11 1023997 390387 38.12%
2026-08-10 831186 342001 41.15%
2026-08-07 225240 45901 20.38%
2026-08-06 38010 20494 53.92%
2026-08-05 42472 20223 47.61%
2026-08-04 63211 31679 50.12%
2026-08-03 98125 51035 52.01%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers POLYMED.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
17 Aug 2023 RISHI BAID Director Sell Market Sale 24950 36774439 10.18% XBRL
14 Aug 2023 RISHI BAID Director Sell Market Sale 99264 146185779 10.21% XBRL
01 Apr 2022 RISHI BAID Director Sell Market Sale 30000 28308980 10.32% XBRL
29 Mar 2022 RISHI BAID Director Sell Market Sale 60000 50860424 10.35% XBRL
28 Mar 2022 RISHI BAID Director Sell Market Sale 10000 8469419 10.41% XBRL
01 Jul 2021 VCB TRADING LLP Promoter Group Sell Market Sale 100000 99500000 3.69% XBRL
11 Mar 2020 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Sell Market Sale 900 278520 0.04% XBRL
11 Mar 2020 NIDHI OSWAL (DAUGHTER OF CFO) Immediate relative Sell Market Sale 210 64981 0.00% XBRL
11 Mar 2020 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 450 130054 0.04% XBRL
27 Dec 2019 M/S. POLYCURE MARTECH LIMITED Promoter Group Buy Market Purchase 2000 413400 0.01% XBRL
23 Jul 2018 HIMANSHU BAID Promoters Sell Market Sale 167000 36561083 8.96% XBRL
23 Jul 2018 RISHI BAID Promoters Buy Market Purchase 167000 36561083 11.33% XBRL
09 Apr 2018 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 300 77923 0.04%
09 Apr 2018 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 71 18330 0.04%
25 Jan 2018 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 650 168925 0.04%
23 Jan 2018 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 1561 411681 0.04%
18 Sep 2017 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Sell Market Sale 3459 827102 0.04%
02 Sep 2017 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 1008 208876 0.05%
21 Aug 2017 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 377 79074 0.04%
21 Aug 2017 JAS KARAN SANCHETI OSWALj Key Managerial Personnel Buy Market Purchase 800 165942 0.04%

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers POLYMED.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹1719.40 INR (live) · fetched 2026-08-23 23:43 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score

Ratios

P/E
54.10
P/E = Price / EPS
Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹1,719.40 / (₹3,221,396,000 / 101,359,400 shares) = ₹1,719.40 / ₹31.78 EPS
FY2025-26 · Annual filing
ROE
10.37%
ROE = Net Income / Shareholder Equity
Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹3,221,396,000 / ₹31,061,727,000 = 10.37%
FY2025-26 · Annual filing
Debt/Equity
0.11
Debt/Equity = Total Debt / Shareholder Equity
Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹3,416,175,000 / ₹31,061,727,000 = 0.11
FY2025-26 · Annual filing
Current Ratio
3.37
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹19,417,332,000 / ₹5,755,224,000 = 3.37
FY2025-26 · Annual filing
ROCE
12.96%
ROCE = EBIT / (Shareholder Equity + Total Debt)
Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹4,468,821,000 / (₹31,061,727,000 + ₹3,416,175,000) = 12.96%
FY2025-26 · Annual filing
Dividend Yield
0.20%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹354,310,000 / 101,359,400 shares) / ₹1,719.40 = ₹3.50 / ₹1,719.40
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 3.0y actual) 18.9%
Net Profit (3y) 21.6%
Revenue (5y, 3.0y actual) 18.9%
Net Profit (5y) 21.6%
Revenue (10y, 3.0y actual) 18.9%
Net Profit (10y) 21.6%

Operating Margin Trend

Expanding

FY2022-23 21.9%
FY2023-24 25.7%
FY2024-25 27.5%
FY2025-26 23.8%

ROCE Trajectory

FY2022-23 17.6%
FY2023-24 21.5%
FY2024-25 15.6%
FY2025-26 12.8%

Earnings Quality

No persistent gap detected

Net Profit CAGR 21.57% vs CFO CAGR 8.04% over 3.0y (2023-03-31 → 2026-03-31); most recent year: Net Profit -4.85% vs CFO -0.17%

Sector-Relative Percentile (Healthcare)

ROE 24th
ROCE 20th
Debt/Equity 50th
P/E 43th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹378.07 Cr. ₹384.78 Cr. ₹420.02 Cr. ₹424.21 Cr. ₹440.83 Cr. ₹403.21 Cr. ₹443.88 Cr. ₹493.66 Cr. ₹534.51 Cr. ₹525.38 Cr. RevenueFromOperations
Net Profit ₹68.36 Cr. ₹74.04 Cr. ₹87.45 Cr. ₹85.23 Cr. ₹91.83 Cr. ₹93.08 Cr. ₹91.83 Cr. incl. minority ₹91.80 Cr. ₹70.93 Cr. incl. minority ₹70.81 Cr. ₹66.29 Cr. incl. minority ₹65.04 Cr. ₹86.03 Cr. incl. minority ₹85.27 Cr. ProfitOrLossAttributableToOwnersOfParent

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers POLYMED.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent3221396000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital101359400.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets19417332000.0
CurrentLiabilities5755224000.0
EquityAttributableToOwnersOfParent31061727000.0
BorrowingsCurrent + BorrowingsNoncurrent3416175000.0

My notes